The patent EP3192882 granted in July 31, 2019 discloses method of production of Potassium Antimony Tartrate (PAT) by utlizing waste products bearing antimony. Potassium Antimony Tartrate (PAT) is consumed by Zinc hydro smelters for purification of Zinc Sulphate solution to produce Zinc metal. The USA and India equivalents of this patent are under processing. The patented process has been commercialized and is running successfully at […]
On Aug. 20, 2019, High Court of Delhi Passed order that “Patent infringement actions are maintainable only in respect of granted and live patents.” Plaintiff: Novartis AG & ANR. . Defendant: Natco Pharma Ltd. The suit concerns the Plaintiff’s patent number IN 276026 titled ‘Novel Pyrimidine Compounds and Compositions as Protein Kinase Inhibitors” relating Ceritinib drug for treating non-small cell […]
Biotechnology is any technique that uses living organisms (or parts of organisms) to make or modify products, to improve plants or animals or to develop micro-organisms for specific uses. The 21st century is the Age of Biotechnology and most important technological breakthroughs have been occurring during the last two decades. The biotechnology revolution has put a great strain on the legal […]
Relaxo Footwears on Saturday said it has reached a settlement with competitor Bata India over the use of trademark ‘SPARX’ in favour of Relaxo Footwears “The company has executed a deed of settlement with Bata India for assignment of trademark ‘SPARX’ in favour of Relaxo Footwears Ltd,” Relaxo Footwears said in a filing to the BSE In 2009, Bata sued Relaxo […]
The revised guidelines for the examination of the patent applications in the domain of computer related inventions (CRI) was recently published by the Indian Patent Office. The notable changes in the modified guidelines are as follows: Section 3(k) of the Indian Patents Act excludes mathematical or business methods, algorithms and computer programs per se from the scope of patentable subject […]
The US Supreme Court last month (June 12, 2017) in Sandoz v. Amgen ruled unanimously in favor of generic that biosimilar companies will not have to wait an additional six months after FDA approval to launch their product. The case concern a biologic product filgrastim marketed by Amgen as Neupogen since 1991 and claims to hold patents on methods of […]
The Federal Circuit on Aug 1, 2016, upheld a district court’s summary judgment against Electric in Electric Power Group, LLC v. Alstom S.A., No. 2015-1778 (Fed. Cir. Aug. 1, 2016). This case involves the eligibility for patenting, under 35 U.S.C. § 101, of certain claims of three of Electric Power Group, LLC’s patents, U.S. Patent Nos. 7233843, 8060259, and 8401710. Electric’s claims […]
Recent trends in disputes over patent validity in USPTO proceedings and in federal courts have raised concerns about the overall validity of patents issued by USPTO. Some observers, citing the extent to which the validity of granted patents has been successfully challenged, believe that USPTO examiners do not always identify the most relevant prior art, which has resulted in granting […]
Original New Drug Application (NDA and BLA) New molecular entity_ Approvals-May 2016 Active Ingredient(s); Drug name Company Approval Date FLUCICLOVINE; AXUMIN (NDA) BLUE EARTH DIAGNOSTICS LTD 27/05/2016 DACLIZUMAB; ZINBRYTA (BLA) BIOGEN 27/05/2016
While India has always been an innovative society, much of the intellectual property (IP) created remains unprotected both on account of lack of awareness and the perception that IP protection is either not required or that the process to obtain it is unnecessarily complicated. The rationale for the National IPR Policy lies in the need to create awareness about the […]